J&J Innovation Podcast Features CureMatch’s Stephane Richard
Thanks to Johnson & Johnson for the opportunity to be part of the J&J Innovation Podcast series featuring CureMatch’s COO Stephane Richard. J&J’s host, Caroline Baratz goes in depth to discover more about the people behind innovative companies ushering in the latest trends in healthcare.
Dr. Richard has been an integral part of the San Diego biotech science community and is a champion for the cancer-fighting company, CureMatch. In this episode, he shares the experiences and passion that motivates him as part of the leadership team for a startup offering a decision support platform whose mission is to sort, find, and match the right cancer treatments. CureMatch is an innovative technology birthed from the UCSD Moores Cancer Center via a few bright minds and a great team with a desire to usher in new innovation to beat cancer.
Let’s Get Personal: Using AI to Rank Cancer Drug Combinations for Precision Medicine
In this episode of the J&J Innovation Podcast, sit down with Stephane Richard, of CureMatch, and learn how his company is attempting to change oncology care through precision medicine.
Let’s listen in…
We hope you enjoyed the podcast and thanks again to those that make the J&J Innovation series possible and to Caroline Baratz for her insightful questions. If you want to hear more fascinating episodes of innovation and the latest trends in healthcare, check out the other series available at J&J Innovation.
About J&J Innovation
Johnson & Johnson Innovation seeks to positively impact human health through innovation. We do this by helping entrepreneurs realize their dreams of creating healthcare solutions that improve peoples’ lives around the world. We work side-by-side with innovators throughout their journey, providing a robust exchange of ideas and resources to support their success. The J&J Innovation Podcast covers the latest trends in Healthcare, starting with the BIO2017 conference in San Diego, CA.
CureMatch, Inc. is a digital precision oncology company bridging the gap between legacy cancer treatments and advances in personalized medicine. CureMatch scores and ranks Personalized Combination Therapy® options to target specific molecular aberrations in cost-effective PreciGENE reports. This actionable intelligence guides oncologists to effectively customize treatment for each individual patient. Based in San Diego, CA, the CureMatch technology has an expert foundation in supercomputing, oncology, genetics, proteomics, biochemistry, and cell biology. For more information, visit www.curematch.com.